Works matching IS 17762596 AND DT 2012 AND VI 7
Results: 48
Hyperbaric oxygen therapy and cancer--a review.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
- Published in:
- 2012
- By:
- Publication type:
- Correction Notice
Biosimilars and market access: a question of comparability and costs?
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 227, doi. 10.1007/s11523-011-0192-7
- By:
- Publication type:
- Article
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 243, doi. 10.1007/s11523-012-0221-1
- By:
- Publication type:
- Article
Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 213, doi. 10.1007/s11523-012-0223-z
- By:
- Publication type:
- Article
Hyperbaric oxygen therapy and cancer-a review.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 233, doi. 10.1007/s11523-012-0233-x
- By:
- Publication type:
- Article
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 247, doi. 10.1007/s11523-012-0235-8
- By:
- Publication type:
- Article
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 253, doi. 10.1007/s11523-012-0237-6
- By:
- Publication type:
- Article
Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 4, p. 217, doi. 10.1007/s11523-012-0236-7
- By:
- Publication type:
- Article
Oncology in 2012: from personalized medicine to precision medicine.
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Inhibition of mTOR in carcinoid tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 189, doi. 10.1007/s11523-012-0225-x
- By:
- Publication type:
- Article
Profiling mTOR pathway in neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 183, doi. 10.1007/s11523-012-0226-9
- By:
- Publication type:
- Article
Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 161, doi. 10.1007/s11523-012-0224-y
- By:
- Publication type:
- Article
New treatment options with cytotoxic agents in neuroendocrine tumours.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 169, doi. 10.1007/s11523-012-0228-7
- By:
- Publication type:
- Article
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 153, doi. 10.1007/s11523-012-0230-0
- By:
- Publication type:
- Article
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 173, doi. 10.1007/s11523-012-0229-6
- By:
- Publication type:
- Article
Erratum to: Inhibition of mTOR in carcinoid tumors.
- Published in:
- 2012
- By:
- Publication type:
- Correction Notice
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 3, p. 199, doi. 10.1007/s11523-012-0227-8
- By:
- Publication type:
- Article
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 145, doi. 10.1007/s11523-012-0214-0
- By:
- Publication type:
- Article
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 127, doi. 10.1007/s11523-012-0216-y
- By:
- Publication type:
- Article
Expression of metastasis-associated protein 2 (MTA2) might predict proliferation in non-small cell lung cancer.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 135, doi. 10.1007/s11523-012-0215-z
- By:
- Publication type:
- Article
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 99, doi. 10.1007/s11523-012-0218-9
- By:
- Publication type:
- Article
Relevance of angiogenesis in neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 93, doi. 10.1007/s11523-012-0217-x
- By:
- Publication type:
- Article
Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 107, doi. 10.1007/s11523-012-0219-8
- By:
- Publication type:
- Article
Sunitinib in pancreatic neuroendocrine tumors.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 117, doi. 10.1007/s11523-012-0220-2
- By:
- Publication type:
- Article
New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Risk management of biosimilars in oncology: each medicine is a work in progress.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Presently available biosimilars in hematology-oncology: G-CSF.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Biosimilars: Is absence of proof of difference, proof of absence of difference?
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
The economic pressures for biosimilar drug use in cancer medicine.
- Published in:
- Targeted Oncology, 2012, v. 7, p. 57, doi. 10.1007/s11523-011-0196-3
- By:
- Publication type:
- Article
Biosimilars: Is absence of proof of difference, proof of absence of difference?
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Colony stimulating factors (CSF) biosimilars. Progress?
- Published in:
- Targeted Oncology, 2012, v. 7, p. 17, doi. 10.1007/s11523-011-0189-2
- By:
- Publication type:
- Article
Erythropoietin biosimilars currently available in hematology-oncology.
- Published in:
- Targeted Oncology, 2012, v. 7, p. 25, doi. 10.1007/s11523-011-0191-8
- By:
- Publication type:
- Article
Presently available biosimilars in hematology-oncology: G-CSF.
- Published in:
- Targeted Oncology, 2012, v. 7, p. 29, doi. 10.1007/s11523-011-0190-9
- By:
- Publication type:
- Article
What do prescribers think of biosimilars?
- Published in:
- Targeted Oncology, 2012, v. 7, p. 51, doi. 10.1007/s11523-011-0193-6
- By:
- Publication type:
- Article
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
- Published in:
- Targeted Oncology, 2012, v. 7, p. 35, doi. 10.1007/s11523-011-0194-5
- By:
- Publication type:
- Article
Risk management of biosimilars in oncology: each medicine is a work in progress.
- Published in:
- Targeted Oncology, 2012, v. 7, p. 43, doi. 10.1007/s11523-011-0188-3
- By:
- Publication type:
- Article
Biosimilar rhG-CSFs: how similar are they?
- Published in:
- Targeted Oncology, 2012, v. 7, p. 3, doi. 10.1007/s11523-011-0187-4
- By:
- Publication type:
- Article
Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Targeting regulatory T cells.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 15, doi. 10.1007/s11523-012-0208-y
- By:
- Publication type:
- Article
Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 3, doi. 10.1007/s11523-012-0207-z
- By:
- Publication type:
- Article
Recent successes of cancer immunotherapy: a new dimension in personalized medicine?
- Published in:
- 2012
- By:
- Publication type:
- Editorial
A review on various targeted anticancer therapies.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 69, doi. 10.1007/s11523-012-0212-2
- By:
- Publication type:
- Article
Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 55, doi. 10.1007/s11523-012-0210-4
- By:
- Publication type:
- Article
Advancement in the research on vascular endothelial growth inhibitor (VEGI).
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 87, doi. 10.1007/s11523-012-0206-0
- By:
- Publication type:
- Article
Targeting pattern recognition receptors in cancer immunotherapy.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 1, p. 29, doi. 10.1007/s11523-012-0213-1
- By:
- Publication type:
- Article